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RESOURCE/METHODOLOGY
Repurposing CRISPR/Cas9 for in situ
functional assays
Abba Malina,1,6 John R. Mills,1,6,7 Regina Cencic,1 Yifei Yan,2 James Fraser,1 Laura M. Schippers,1
Marile`ne Paquet,3 Jose´e Dostie,1 and Jerry Pelletier1,4,5,8
1Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6 Canada,; 2De´partement de Biochimie et Me´decine
Mole´culaire, Universite´ de Montre´al, Quebec H3C 3J7, Canada; 3De´partement de Pathologie et de Microbiologie, Faculte´ de
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University, Montreal, Quebec H3G 1Y6, Canada; 5The Rosalind and Morris Goodman Cancer Research Center, McGill
University, Montreal, Quebec H3G 1Y6, Canada
RNAi combined with next-generation sequencing has proven to be a powerful and cost-effective genetic screening
platform in mammalian cells. Still, this technology has its limitations and is incompatible with in situ
mutagenesis screens on a genome-wide scale. Using p53 as a proof-of-principle target, we readapted the CRISPR
(clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated 9) genome-editing system to
demonstrate the feasibility of this methodology for targeted gene disruption positive selection assays. By using
novel ‘‘all-in-one’’ lentiviral and retroviral delivery vectors heterologously expressing both a codon-optimized Cas9
and its synthetic guide RNA (sgRNA), we show robust selection for the CRISPR-modified Trp53 locus following
drug treatment. Furthermore, by linking Cas9 expression to GFP fluorescence, we use an ‘‘all-in-one’’ system to
track disrupted Trp53 in chemoresistant lymphomas in the Em-myc mouse model. Deep sequencing analysis of
the tumor-derived endogenous Cas9-modified Trp53 locus revealed a wide spectrum of mutants that were
enriched with seemingly limited off-target effects. Taken together, these results establish Cas9 genome editing as
a powerful and practical approach for positive in situ genetic screens.
[Keywords: Cas9; CRISPR; genome editing; functional screening; p53]
Supplemental material is available for this article.
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Modern high-throughput DNA sequencing technologies
and their corresponding genome-wide analysis tools have
led to an unprecedented amount of publicly available
genomic information. However, technologies that are
able to capture and translate such a wealth of genetic
knowledge and gene regulation into predictive biological
models and systems have been lagging (Dow and Lowe
2012). The discovery and exploitation of RNAi has helped
close this gap (Chang et al. 2006) and has proven to be
a powerful mammalian genetic testing and screening tool
but is limited to targeting the exome, and often such
mRNA-specific knockdown is only partial or incom-
plete. Moreover, understanding the biological relevance
of gene-specific gain-of-function mutations in cell and
animal models is currently incompatible with features of
RNAi. The development of modern genome engineering
technologies based on modular DNA-binding proteins
coupled to nucleases, such as zinc finger nucleases
(ZFNs) or transcription activator-like effector nucleases
(TALENs), has shown tremendous promise for achieving
these goals (Gaj et al. 2013). However, in their present
technological states, both are cumbersomely large to use
and labor-intensive to produce and rely on prior extensive
empirical testing to identify appropriate gene targeting
pairs, making either technology impractical and not cost-
effective for scaling up in genome-wide studies.
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There has been much enthusiasm of late in the de-
velopment of components of CRISPR (clustered regularly
interspaced short palindromic repeats) as an alternative
genome-editing system. The CRISPR locus constitutes an
ancient and pervasive bacterial and archeal acquired
immune system, with its defining characteristic being
the use of short complementary CRISPR RNA sequences
(crRNAs) that bind to and direct cleavage of foreign
invading DNA (and sometimes RNA) molecules in a se-
quence-specific manner (Sorek et al. 2013). These short
crRNA strands originate from a processed longer pre-
crRNA transcript that consists of tandem units of palin-
dromic repeat sequences separating short distinct proto-
spacer fragments of foreign DNA sequence that have been
integrated into the locus from prior infection events.
Several different classes of CRISPR operons have been
characterized to date, and while all share these basic
hallmarks and steps (foreign DNA integration, crRNA
maturation, and crRNA-directed cleavage), they distin-
guish themselves through sequence divergence among
their repeat stretches and also by the set of Cas (CRISPR
associated)-encoded proteins that perform all of the
system’s basic functions. Of these, the type II CRISPR
system is perhaps one of the simplest, requiring only
three components to execute its DNA interference: one
Cas protein (Cas9) that acts as both endonuclease and
RNA chaperone and two auxiliary RNAs, the requisite
processed crRNA molecule and a Cas9-bridging trans-
activating crRNA molecule (tracrRNA) to which the
crRNA hybridizes (Chylinski et al. 2013). All three com-
ponents (specifically from the bacteria Streptococcus
pyogenes) were shown to be sufficient to direct DNA
cleavage when reconstituted in in vitro reactions, with
even further simplification achieved through the fusion
of the crRNA to the tracrRNA using a simple hairpin
linker region (termed a synthetic guide RNA [sgRNA])
(Jinek et al. 2012). Most notably, Cas9-directed site-
specific cleavage can be manipulated by engineering a
complementary sequence that is 20 nucleotides (nt) in
length (referred to here as the ‘‘trigger’’) into the sgRNA,
as long as an 59NGG39 PAM (protospacer-adjacent motif)
is present 39 to the genomically encoded target comple-
ment sequence. The latter serves to distinguish self from
non-self DNA sequences in the CRISPR system.
Building on this system, several groups have shown
that Cas9-mediated genome editing can be achieved in
a wide variety of organisms: bacteria (Jiang et al. 2013a),
yeast (DiCarlo et al. 2013), Caenorhabditis elegans
(Dickinson et al. 2013; Friedland et al. 2013; Katic and
Grosshans 2013), Drosophila (Bassett et al. 2013; Gratz
et al. 2013), zebrafish (Chang et al. 2013; Hwang et al.
2013a,b; Jao et al. 2013), plants (Feng et al. 2013; Jiang
et al. 2013b; Li et al. 2013a; Miao et al. 2013; Nekrasov
et al. 2013; Shan et al. 2013), and rats (Li et al. 2013b) and
mouse and human cells (Cho et al. 2013; Cong et al. 2013;
Ding et al. 2013; Jinek et al. 2013; Mali et al. 2013; Shen
et al. 2013; Yang et al. 2013). In addition, sgRNAs can be
multiplexed to simultaneously achieve genome-editing
outcomes at as many as five independent loci in a single
cell (Wang et al. 2013). Here, we sought to further extend
the utility of the Cas9 genome-editing platform by de-
veloping a framework for its use in positive selection
screening approaches both in vitro and in vivo using p53
as a model genetic target.
Results
In vitro validation of a single-vector lentiviral-derived
Cas9 genome-editing construct
Based on the work by Jinek et al. (2012) and in the same
vein as other groups (Cong et al. 2013; Gilbert et al. 2013;
Hsu et al. 2013; Mali et al. 2013; Qi et al. 2013), we chose
to adapt S. pyogenes Cas9 for genome editing in mam-
malian cells. It is worth noting those features of our Cas9/
sgRNA-based construct that distinguish it and are shared
with those that are currently publicly available (Figs.
1A,B; Supplemental Fig. 1): (1) The coding sequence of
Cas9 from S. pyogeneswas extensively altered for optimal
mammalian codon usage bias, with several restriction
sites eliminated (Cong et al. 2013; Jinek et al. 2013; Mali
et al. 2013). (2)We fused a 3xFlag epitope to theN terminus
as an affinity tag flanked by two NLS (nuclear localization
signal) tags (one derived from SV40 large Tantigen, and the
other derived from nucleoplasmin) for efficient nuclear
import. (3) We based our hybrid crRNA:tracrRNA sgRNA
on what had been described previously (Jiang et al. 2013a)
but instead used a longer, more complete tracrRNA
sequence that has been subsequently shown to promote
more efficient cleavage on a greater number of target sites
by Cas9 (Cong et al. 2013; Hsu et al. 2013; Jinek et al.
2013; Mali et al. 2013; Wang et al. 2013). Most impor-
tantly, we chose to express both the sgRNA and Cas9
gene in a single vector format embedded within a second-
generation self-inactivating (SIN) lentiviral or retroviral
(see below) backbone. This design not only allows for
flexibility in cell type delivery but is also amenable to the
generation of stable single-vector integrants (Cong et al.
2013; Gilbert et al. 2013), a requirement for pooled multi-
plex screening approaches.
To ensure the compatibility of our design with its
intended function as a broad-based genome-editing plat-
form, we used the previously described ‘‘traffic light
reporter’’ (TLR) assay, which measures simultaneously
the frequency of both nonhomologous end-joining (NHEJ)
repair and homology-directed repair (HDR) (Fig. 1C; see
the Materials and Methods; Certo et al. 2011). We mea-
sured the genome-editing efficiencies of several different
Cas9 constructs (with or without donor eGFP repair
plasmid D20 donor) following transient transfection in
a 293T cell line stably expressing a single-copy TLR and
scoring for both green and red fluorescent cells by flow
cytometry (Fig. 1D). Fairly consistent transfection effi-
ciencies across all samples (between;40% and 60% of all
cells) were achieved, as measured by BFP fluorescence
that is coexpressed from the D20 eGFP donor repair
plasmid (data not shown). Transfection of an empty
control vector (pKSII) with or without donor eGFP plas-
mid yielded virtually no background fluorescent protein
expression (Fig. 1D, top two left panels). Transfection of
CRISPR/Cas9 for in situ functional assays
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Cas9-TLR (pLC-TLR) harboring an sgRNA targeting the
TLR eGFP region promoted 3%–4% of cells to be repaired
by NHEJ and, in the presence of the D20 eGFP donor
plasmid, 4% of cells to be repaired by HDR. We note that
our estimates of NHEJ are underreported, since RFP
fluorescence scores for only one-third of all editing
events. Importantly, this effect was specific for the TLR
sgRNA sequence, as no fluorescence events were mea-
sured when the sgRNA corresponded to one that targets
the AAVS1 genomic region.
Strikingly, when comparing the pLC-TLR construct
with that of a well-characterized ZFN pair (VF2468)
(Maeder et al. 2008) that targets a region proximal to
the sgRNA trigger site, the VF2468 ZFN produced a repair
efficiency that was approximately eightfold less despite
showing higher expression levels (Fig. 1D,E). We also
compared the cleavage efficiencies of two mutant Cas9
constructs (D10A and H840A), which eliminate strand-
specific endonuclease activity and behave as nickases
(Supplemental Fig. 1A; Jinek et al. 2012; Cong et al. 2013;
Mali et al. 2013). As expected, both the D10Amutant and
(to a lesser extent) the H840A mutant produced compa-
rable amounts of HDR in the presence of donor plasmid
with almost no detectable mutagenic NHEJ, while the
Cas9 double mutant D10A/H840A had no detectable
double-stranded cutting ability (Fig. 1D). Furthermore,
we tested a C-terminal NLS fusion of Cas9 using this
system (Supplemental Fig. 2), since initial reports (Cong
et al. 2013) indicated reduced activity from N-terminal
fusions. We found this not to be the case when engineered
into the lentiviral plasmid pLeGO (lentiviral ‘‘gene on-
tology’’) (Weber et al. 2008), as the C-terminal domain
(CTD)-Flag construct consistently produced lower levels
of both NHEJ and HDR (Fig. 1D). All N-terminal domain
Figure 1. Genome editing of a TLR locus in 293T cells using an engineered all-in-one type II CRISPR system. (A) Schematic diagram of
LeGO-based lentivirus (pLC) constructs driving expression of Cas9 and sgRNAs. (B) Predicted secondary structure (http://rna.tbi.
univie.ac.at/cgi-bin/RNAfold.cgi) of sgRNA showing alignment of trigger sequence with target and PAM. The first nucleotide of the
trigger sequence is forcibly a G, since the sgRNA is expressed from the murine U6 promoter. (C) Schematic of TLR with the position
and nucleotide sequence of the TLR trigger, PAM, and stop codon shown. (D) A genomically integrated TLR is efficiently targeted by
pLC-TLR. Quantitation of 293T TLR cells transfected with the indicated Cas9/sgRNA expression constructs and, where indicated, in
combination with D20 eGFP. (E) Immunoblot showing expression and subcellular localization of Cas9 from the experiment presented in
D. (C) Cytoplasmic fraction; (M) membrane fraction; (N) nuclear fraction. Blots were probed with the antibodies indicated below each
panel. (F) Lentiviral-mediated NHEJ and HDR in 293T TLR cells. Cells were infected with lentivirus expressing Cas9 and the
corresponding sgRNA and analyzed by flow cytometry 6 d later. The D20 eGFP donor plasmid was introduced by transfection 1 d prior
to transduction with the Cas9/sgRNA lentiviral construct.
Malina et al.
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(NTD)-tagged Cas9 constructs as well as the VF2468 ZNF
pair showed preferential nuclear localization (Fig. 1E,
lanes 4–18), whereas CTD-tagged Cas9 showed a simi-
lar distribution between the cytoplasm and the nucleus
(Fig. 1E, lanes 19–21), perhaps explaining the differences
seen in repair efficiencies. Finally, our Cas9 lentiviral
constructs produced comparable levels of NHEJ and HDR
following transduction of virus into the TLR 293T cell
line, enabling one to perform genome editing in a broader
range of cell types (Fig. 1F). In sum, our combined Cas9–
sgRNA-expressing single-vector lentiviral construct of-
fers a convenient and adaptable template for in situ genome
modification in cells.
Endogenous gene targeting
Having functionally validated our Cas9 system using an
exogenously synthetic reporter locus, we next sought to
target an endogenous gene. We chose to target exon 7 of
Trp53 as a suitable candidate for mutagenesis in a positive
selection assay, as this region is frequently mutated in
a wide range of tumor types (commonly referred to as
a p53 ‘‘hot spot’’ region) and can confer resistance to DNA
damage-inducing chemotherapy (Supplemental Fig. 3;
Oren and Rotter 2010). Because we ultimately wanted
to trackCas9-mediatedmutagenesis in a livemousemodel,
we linked Cas9 to eGFP as a facile means to monitor its
expression and as an indirect indicator for potential
genome-editing events (Fig. 2A). We also transferred our
expression cassette into a SIN-based MMLV-based vector
backbone, which, in our hands, has proven to be a more
reliable means of transducing lymphocytic mouse cells
(data not shown). We chose to test for Cas9-driven targeted
mutagenesis on the endogenous Trp53 gene in mouse
embryonic fibroblasts (MEFs), a cell line in which the
biology of p53 has been thoroughly characterized and
where the gene is structurally intact. Both Arf/ MEFs
(p53-proficient) and p53/ MEFs were transduced with
Figure 2. Cas9-mediated editing of Trp53 in Arf/ MEFs leads to Nutlin-3a resistance. (A) Schematic diagram of the pQ-based
retroviral constructs driving expression of Cas9, GFP, and sgRNAs (pQCiG). (B) Flow cytometric analysis of Arf/ and p53/ MEFs
transduced with QCiG-Rosa, QCiG-p53, or MLP-p53.1224 retroviruses, cultured 3 d later in the presence of vehicle or 10 mMNutlin-3a
for 24 h, and then allowed to recover for 4 d. (C) Colony formation assay of infected Arf/ and p53/ MEFs with QCiG-Rosa, QCiG-
p53, or MLP-p53.1224. Five-thousand cells were seeded, exposed to 10 mM Nutlin-3a for 24 h, and allowed to recover for 12 d in the
absence of drug, at which point they were stained with crystal violet. (D) SURVEYOR assay of DNA isolated from QCiG-p53- and
QCiG-Rosa-infected Arf/ MEFs exposed to 10 mM Nutlin-3a for 24 h and allowed to recover for 4 d. The arrowhead denotes the
expected SURVEYOR cleavage products. (E) Immunoblot documenting Cas9 and p53 expression in QCiG- and MLP-infected MEFs. The
asterisk denotes the position of a prominent p53 truncated product.
CRISPR/Cas9 for in situ functional assays
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retroviruses expressing an sgRNA/Cas9 construct target-
ing either Rosa26 (which served as a neutral endogenous
target) or Trp53, which we termed pQCiG-Rosa and
pQCiG-p53, respectively. A previously validated short
hairpin construct against p53 (p53.1224) that also coex-
presses GFP served as a positive control (Dickins et al.
2005). Seventy-two hours post-transduction, cells were
cultured in the presence or absence ofNutlin-3a, a specific
inhibitor of the MDM2–p53 interaction (Tovar et al.
2006). Cells were scored for the fraction of GFP+ cells
after 4 d of Nutlin-3a exposure using flow cytometry
(Fig. 2B). Nutlin-3a potently activates a p53-dependent
anti-proliferative cellular response, which strongly and
specifically selects for any cells with disrupted Trp53
function (Efeyan et al. 2007). Much like MLP-p53.1224
infected cells, the pQCiG-p53 GFP+ cells were rapidly
enriched for in the presence of Nutlin-3a, suggesting
that CRISPR-mediated gene disruption had initially oc-
curred in at least a proportion of the initial Cas9-express-
ing cells. This is in contrast to pQCiG-Rosa-infected cells
whose GFP+ proportion remained constant throughout
the assay. Crucially, all of the effects from exposure to
Nutlin-3a were completely eliminated when performed
in p53/ MEFs, suggesting that the selected GFP+ cell
population originated from a pool of cells with a Cas9-
induced p53 gene disruption and not due to any off-target
effects (Fig. 2B). Further reinforcing this notion, alternate
trigger sequences targeting exons 5, 6, and 8 of Trp53
(Supplemental Fig. 3B) also promoted the strong selection
for GFP+ cells in the presence of Nutlin-3a (Supplemental
Fig. 4A), making it unlikely that separate altered genomic
regions contributed to this phenotype. Moreover, it is
worth pointing out that in all of these experiments, Cas9-
linked GFP expression was stable over time, indicating
that continuous Cas9 expression is not toxic to cells (Fig.
2B; see below).
Similar results were obtained in a separate colony
formation assay, where low numbers of transduced cells
were allowed to proliferate over the course of 10 d in the
presence or absence of Nutlin-3a (Fig. 2C; Supplemental
Fig. 4B). Here, in the presence of Nutlin-3a, the pQCiG-
p53-infected population formed ample size colonies, much
like their MLP-p53.1224 counterparts, while the prolifer-
ative defects of pQCiG-Rosa-infected cells became quite
apparent (Fig. 2C). At the molecular level, we detected an
insertion/deletion (indel) frequency that ranged from 4%
to 36% at the Trp53 locus in the pQCiG-p53-infected
cells (Fig. 2D; Supplemental Fig. 4C), while no mutated
Trp53 alleles could be distinguished among pQCiG-Rosa-
infected cells (Fig. 2D). By immunoblotting, we could also
detect the presence of truncated p53 protein products from
extracts ofArf/-infected pQCiG-p53 samples, consistent
with aTrp53 reading frameshift followingNHEJ repair (Fig.
2E, lane 4, denoted by the asterisk). Moreover, our ability
to specifically disrupt an endogenous Trp53 locus was not
simply limited to mouse primary cells—we were also able
to successfully mutagenize p53 in U2OS, an osteosarcoma
cell line with an intact TP53 locus (Supplemental Fig. 5).
Here, too, we could readily select for cells with a modified
TP53 locus in the presence of Nutlin-3a, as shown for cells
transduced with LC-hp53 in a similarly designed colony
formation assay (Supplemental Fig. 5A). Multiple trun-
cated p53 protein products were detected in extracts from
pLC-hp53-infected U2OS cells and, in this case, an over-
all reduction in total p53 levels (Supplemental Fig. 5B, cf.
lanes 3 and 2). Thus, we can stably and easily transduce
both mouse and human cell lines in culture with our
Cas9 targeting vector as a means to alter various regions
of an endogenous genetic locus and select for that specific
genome-editing event with no apparent long-term toxic
effects.
Positive in vivo selection of targeted Cas9-induced p53
gene disruption
Having established the simplicity of our Cas9 setup to
target and select for an altered Trp53 locus in cell culture,
we next wanted to know whether we could adapt this
for use in a mouse model of cancer. We chose to use the
Em-myc mouse as a candidate model, in part due to the
ease with which ex vivo retroviral transduction of B-cell
lymphomas can be accomplished, the fact that multiple
cohorts of syngeneic mice can be rapidly generated, and
the reliable and predictable p53 tumor response that can
be elicited from a clinically relevant therapeutic inter-
vention. Moreover, very low numbers of injectable cells
are required for propagating Em-myc-driven lymphoma-
genesis in mice, and thus almost every cell can individ-
ually contribute to tumor formation following transplan-
tation (Kelly et al. 2007). This mouse model is therefore
uniquely suitable for performing in vivo screens. As
before, we first tested the ability to select for Cas9-
modified Trp53 in Arf/Em-myc lymphomas in vitro
using a fitness assay (Supplemental Fig. 6). Cells were
partially transduced with QCiG-p53 or QCiG-Rosa Cas9
targeting vectors along with MLP-p53.1224 as a positive
control; treated with either Nutlin-3a, doxorubicin
(DXR), or vehicle; and allowed to divide over the course
of 3 d. No toxicity was observed from expression of either
Cas9 construct, as the initial GFP expression remained
constant over time in the presence of vehicle treatment
(Supplemental Fig. 6). When compared with vehicle,
there was an obvious and substantial shift in the fluores-
cence peak following Nutlin-3a or DXR treatment that
was only apparent for QCiG-p53-infected cells but not for
the QCiG-Rosa-infected cells (Supplemental Fig. 6).
These effects also appeared to be entirely reliant on the
p53-dependent DNA damage-induced apoptotic response,
since enrichment for GFP observed in the presence of
drug was not apparent in p53/Em-myc lymphomas or
Em-myc lymphomas overexpressing Bcl-2 for either
QCiG-p53 or MLP-p53.1224 (Supplemental Fig. 6).
We next sought to corroborate these results in vivo in
mice. Cohorts of mice were injected with equivalent
amounts of the same ex vivo sgRNA–Cas9-transduced
Arf/Em-myc lymphoma cells as described above. Once
lymphomas had developed and were palpable, mice were
separated into two groups and received a single injection
of either DXR or vehicle (Fig. 3A). The Arf/Em-myc
tumors infected with QCiG-Rosa readily responded to
Malina et al.
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DXR therapy, with regression occurring almost immedi-
ately followed by a tumor-free remission lasting a median
of 8 d (Fig. 3B). In contrast, all other tumor types showed
complete resistance to DXR treatment (Fig. 3B). Dissec-
tion of moribund QCiG-p53 mice revealed a pronounced
GFP fluorescence from various lymphoid tissues and
lymphomas (Fig. 3C). Extraction and disaggregation fol-
lowed by FACS analysis of cells and tissues at various
stages of lymphomagenesis (preinjection, post-injection
[pre-DXR], and post-DXR treatment) confirmed that GFP
fluorescence was due to progressive enrichment of the
QCiG-p53-expressing lymphoma cells (much like what
was seen for MLP-p53.1224) (Fig. 3D). In contrast, QCiG-
Rosa-expressing lymphoma cells were not enriched (Fig. 3D).
Importantly, this result was dependent on a prior intact
p53 gene, as the entire selective pressure for QCiG-p53
expression was eliminated in p53/Em-myc lymphomas
following DXR treatment, implying that exon 7 of
Trp53 in Arf/Em-myc cells had been altered by Cas9.
Clear evidence of mutation was confirmed using the
SURVEYOR assay, showing an indel frequency of 19% (Fig.
3E). Furthermore, immunoblots comparing protein ex-
tracts from dissected lymphomas pre- and post-DXR
treatment revealed a strong preference for elevated Cas9
expression in the DXR-treated QCiG-p53 samples relative
toQCiG-Rosa controls, which correlatedwith the increase
in the proportion of GFP+ cells as seen by flow cytometry
(Fig. 3F). Strikingly, in addition to the accumulation of
Figure 3. Cas9-mediated editing of Trp53 in Arf/Em-myc lymphomas is positively selected for following DXR treatment in vivo.
(A) Schematic diagram of in vivo fitness assay. (B) Kaplan-Meier analysis of tumor-free survival of mice injected with Rosa26 or Trp53
Cas9 targeted Arf/Em-myc and p53/Em-myc lymphomas following treatment with DXR. (C) Detection of GFP in tumors arising
from QCiG-p53-infected Arf/Em-myc lymphomas following exposure to DXR and analyzed 3 d later. White arrows denote GFP
fluorescence in lymph nodes originating from the presence of QCiG-p53 in the resulting tumors. (D) FACS analysis of the indicated
Cas9 targeted Em-myc lymphomas analyzed before injection into mice (input), from tumors arising in vivo (pre-DXR), and from tumors
for which the host had received DXR treatment (post-DXR). (E) SURVEYOR assay of DNA from QCiG-p53- and QCiG-Rosa-infected
Arf/Em-myc lymphomas isolated from mice prior to DXR treatment. (F) Immunoblot showing long-term Cas9, p53, and GFP
expression in QCiG-Rosa and QCiG-p53 Arf/Em-Myc lymphomas in vivo. Samples are from three separate tumors isolated prior to
(pre-DXR) or following (post-DXR) DXR treatment. In the case of post-DXR samples for QCiG-Rosa Arf/Em-myc lymphomas, tumors
were harvested after relapse (;10 d after post-DXR treatment). The asterisk highlights a truncated p53 protein arising in the Cas9-
edited samples.
CRISPR/Cas9 for in situ functional assays
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lower truncated p53 protein products in the QCiG-p53
samples followingDXRtreatment, therewas also amarked
increase in the total levels of p53 expression, a likely result
of a dominant-negative mutant interaction (see the Dis-
cussion). Taken together, these results demonstrate the
feasibility and practicality of using CRISPR as a tool for
positive selective screening approaches in mouse models
of cancer.
The spectrum of mutations derived from CRISPR-
mediated Trp53 targeted cleavage
One of the unique features of CRISPR-driven mutagenesis
is the initial mixture of mutational events that arises in
a pool of cells from NHEJ repair. Genetic mutations
conferring unique growth advantages should be selected
for, potentially yielding novel biological insight into the
target gene’s cellular role. Spurred by our previous
results, we decided to look in more detail at the
dynamics of the mutational spectrum over the course
of drug treatment that arose following repair of the
double-strand breaks induced by Cas9 targeted cleavage
in Trp53 exon 7. Deep sequencing was performed on
DNA isolated from Arf/ MEFs and Arf/Em-myc
lymphoma cells both pre- and post-drug treatment (Fig.
4). As expected from previous studies, a majority of the
indels that occur after NHEJ repair centered on the
predicted Cas9 cleavage site (;4 nt 59 to the PAM site)
Figure 4. Analysis of indels at the Trp53 locus and at predicted off-target sites in Arf/MEFs and Arf/Em-myc tumors edited with
Rosa26 and Trp53 sgRNAs. (A) Total count and location of insertions and deletions in exon 7 of Trp53 in Arf/Em-myc cells prior to
injection, post-implantation, and post-DXR treatment, respectively. The vertical dashed line represents the predicted Cas9 cleavage
site. (B) Frequency of mutant reads obtained following sequencing of Trp53 exon 7 from the indicated cells and tumors. T-1, T-2, and T-3
represent three independent tumors. (C, top panel) Sequence alignment of the trigger site in the Trp53 and Trp53 pseudogene.
Differences are highlighted in green. (Bottom panel) Pie charts illustrating the proportion of mutated sequence reads at Trp53 (left) and
the Trp53 pseudogene (right) relative to wild-type sequences (wt; blue). DNA was isolated from samples of Arf/Em-myc lymphoma
cells infected with QCiG-Rosa-infected (top), QCiG-p53-infected (middle), or QCiG-p53-infected cells that were exposed to 10 mM
Nutlin-3a for 3 d followed by a 10-d recovery period (bottom). (D) Prediction of genomic sequences showing sequences complementary
to the first 13 perfectly matched nucleotides 59 to the PAM of the Trp53 trigger sequence with all possible combinations of PAM. The
trigger sequence is shown in blue, PAM is in red, and flanking nucleotides are in black. The genomic location is shown at the right. (E)
Percent mutant reads at the indicated genomic locus in Rosa26- and Trp53-modified Arf/ MEFs. The total read count for each
amplified region ranged from ;11,000 to 15,000 (sample #8), ;18,000 to 23,000 (sample #7), and ;20,000 to 53,000 (all others). Read
counts for locus #2 are absent, since the barcode that had been used in the preparation of that sample could not be deciphered from the
output of reads.
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(Fig. 4A). The total number of mutations increased
following exposure to DXR in tumor cells, from an
initial average NHEJ rate of ;10% (among three in-
dependent tumors) to a final average NHEJ rate of;55%
(a fivefold relative increase) (Fig. 4B). We detected
a significant rise in the percentage of mutant Trp53 exon
7 reads in cells infected with QCiG-p53 following either
Nutlin-3a treatment in vitro or DXR treatment in vivo
(about fourfold relative increase) (Fig. 4B), correlating
very tightly with the fold enrichment in GFP-expressing
cells (see Supplemental Fig. 5). Importantly, baseline
mutant reads (<1%) remained constant in all QCiG-Rosa
samples even following drug treatment (Fig. 4B). To an
extent similar to Arf/Em-myc lymphoma cells, the
number of mutant reads in exon 7 of Trp53 increased by
about threefold in QCiG-p53 transduced Arf/ MEFs
following Nutlin-3a treatment but not in their QCiG-
Rosa counterparts, indicating that these effects were not
limited to transformed cells (Supplemental Fig. 7A).
While there was a wide range of nucleotide mismatches
in the p53 target site that arose following drug treatment,
closer inspection of the mutant reads revealed rank order
preferences that were enriched, mostly resulting in frame-
shift mutations (Supplemental Fig. 7B,C).
One interesting result of the deep sequencing analysis
was the almost complete lack of sequencing reads that
contained mutations in the homologous region of the
Trp53 pseudogene (Fig. 4C). Only two mismatches in the
sgRNA target region distinguish Trp53 from the pseudo-
gene. Mutant reads for the Trp53 pseudogene remained
consistently at baseline levels across all samples ana-
lyzed, unlike the p53 mutant reads, indicating the ab-
sence of off-target cutting by Cas9 at this locus (Fig. 4C).
We further analyzed our tumor samples for other pre-
dicted off-target modifications (Fig. 4D). From both the
SURVEYOR assay and deep sequencing reads, only one
(locus #7) of nine potential off-target sites showed con-
sistent Cas9-mediated off-target mutagenesis, as only
QCiG-p53 but not QCiG-Rosa transduced cells demon-
strated this effect (Fig. 4D,E; Supplemental Fig. 7D).
Incidentally, locus #7 had the least number of total
mismatches (two) among all predicted off-target regions,
suggesting that Cas9 cleavage can tolerate a small num-
ber of mismatches in the 59 end of the trigger sequence, in
line with previously reported data (see the Discussion;
Semenova et al. 2011; Jinek et al. 2012). Thus, the repair
of Cas9-induced double-strand breaks in Trp53 enriched
for a wide variety of indels covering a large range of
sequence diversity with seemingly minimal off-target
effects, underscoring the versatility of CRISPR-mediated
in situ genome editing.
Discussion
Versatility and limitations
With the recent emergence and development of se-
quence-specific endonucleases, the prospect of targeting
and editing any genetic element in an organism’s genome
in situ appears within reach. Methodologies and tech-
niques based on ZFNs and TALENs have broadened our
capability of manipulating the genome to the point where
their application as gene therapy is undergoing early-
phase clinical trials (NCT00842634, NCT01044654, and
NCT01252641). Nevertheless, the widespread adoption
of these technologies has been hampered somewhat by
their intrinsic design constraints, which involves the de
novo construction of pairs of lengthy modular DNA-
binding domains for each and every DNA target region
and iterative empirical testing for target modification
efficiency and general cellular toxicity. Thus, in their
current states, converting them for use in genome-wide
studies and screens is hindered by their lack of flexibility
and scalability. The simplicity of the Cas9-based genome-
editing procedure, which uses a single monomeric endo-
nuclease that is guided to the DNA cleavage site through
RNA hybridization, is uniquely suited to resolve many of
these adaption barriers and issues. In this study, we
exploited these unique traits of Cas9/CRISPR to tailor
a version of the Cas9/CRISPR system specifically for
broad in vivo use in a relatively simple platform intended
for implementation in positive-screening approaches.
Central to the general applicability of a modified type
II-based CRISPR system in genome-wide screening ap-
proaches (and, for that matter, in any genome-editing
application) is the ability to target any homologous DNA
sequence through simple alteration of the trigger portion
of the sgRNA, requiring only the partially degenerate
3-base 59NGG39 PAM sequence to be present in the
noncomplementary strand of the targeted region. The
frequency of this motif in standard mammalian genomes
and the small oligo sgRNA design requirement should
allow for the generation of complex pools of targeted
whole-genome sgRNA libraries. In its current embodi-
ment, libraries based on Cas9-driven cleavage are only
amenable to positive selection screening approaches
given the rapid normalization of noncutting or neutral
mutagenic events in the population following DNA cleav-
age and subsequent repair. Nevertheless, when compared
with RNAi, the current gold standard in pooled high-
throughput whole-genome screening approaches, Cas9-
based libraries would offer several advantages. First, un-
like shRNA/siRNA libraries, sgRNA-based libraries
could have a larger targeting range than shRNAs to in-
clude genomic regions responsible for generating non-
coding RNAs as well as probing intronic and intergenic
regions for functional consequences. Second, there is
inherent predictability in Cas9-directed targeted gene
mutation in terms of both the potency of its disruption
(either monoallelic or biallelic) and the permanency of its
alteration, avoiding confusing hypomorphic phenotypes.
Third, the confounding interpretation of off-target effects
should also be greatly reduced, since the probability of
a single sgRNA targetingmultiple exons is greatly diluted
by the sequence space of a whole genome, while off-target
effects arising from shRNA must, out of design, affect
another mRNA. In principle, this also greatly reduces the
need for high ‘‘coverage’’ of distinct sgRNAs targeting
multiple areas of the same transcript, hence reducing
overall pool sizes.
CRISPR/Cas9 for in situ functional assays
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A necessary prerequisite for any CRISPR-based large-
scale multiplex screen is the use of a surrogate marker
for monitoring genome-editing events and ensuring its
stability over the course of the assay. In our design, we
opted for GFP fluorescence as a convenient means to
track genome editing in vivo by linking it to Cas9
expression. While GFP fluorescence cannot be used to
score directly for a mutagenic or gene-disruptive event, it
does allow for enrichment of cells that have undergone
such events (Ding et al. 2013). It is worth noting that
when compared with MLP-p53.1224, the GFP fluores-
cence originating from the pQCiG constructs appears
dimmer (mean fluorescence ;10-fold above baseline),
perhaps a consequence of reduced viral titers owing to
the larger size of the Cas9 cDNA or due to differential
promoter activity between MLP and pQCiG (PGK vs.
SV40) (Supplemental Fig. 6).
Unlike what has been observed for ZFNs or TALENs,
long-term Cas9 expression (even in complex with its
sgRNA) does not appear to be toxic. We observed no
overt loss of expression in cells that continuously pro-
duced Cas9/sgRNA for up to 18 d in culture as well as
24 d in vivo (Fig. 3D; data not shown). More telling is that
the proportion of GFP+ Rosa26 targeted Arf/Em-myc
lymphoma cells remained constant when tumors arose in
vivo and did not change in resistant tumors that arose
following DXR treatment (Fig. 3D). Thus, despite contin-
uous expression of our control Rosa26 targeting Cas9/
sgRNA construct under conditions of strong negative
selective pressure in mouse tissue, our Cas9 variant was
not depleted, demonstrating both the robustness of our
vector design and the neutrality of the CRISPR system.
Mutational spectrum of Cas9-edited Trp53 following
drug selections
Another distinct advantage of CRISPR-based mutagene-
sis screens is the ability to not only induce permanent
and selectable genetic alterations among a diverse set of
genes but also select for distinct mutations within a given
gene. Thus, one has the potential to infer more than
a simple loss-of-function genetic analysis from the output
of mutations that are selected for during a positive
selection CRISPR-based screen. In fact, following our
Cas9-mediated targeted p53 disruption, we observed a
proportion of indels in exon 7 that were selected for
following drug treatment (Supplemental Fig. 7C). While
most of the cancer-linked TP53mutations are distributed
evenly over its coding region, a majority tends to occur
in the DNA transactivation domains that span roughly
exons 4–9. Specifically on exon 7, several ‘‘hot spot’’ mis-
sense mutations (which modify residues G245, R248, and
R249) frequently arise in a wide variety of tumor samples
(Supplemental Fig. 3; Petitjean et al. 2007; Edlund et al.
2012). Many of these mutations permanently affect p53
transcriptional activity and are destabilizing in general
but can also exert dominant-negative effects on wild-type
p53 (through sequestration of the unaffected allelic pro-
tein in a nonfunctional tetrameric complex) or, more
subtly, acquire gain-of-function properties that could con-
fer selective advantages during key stages of the tumori-
genic process (Muller and Vousden 2013). The majority of
the indels generated through Cas9 cleavage in the Em-myc
mouse model that were enriched during drug treatment
were frameshifts causing premature termination at 27
codons or three codons downstream from the PAM. For
both cases, the truncated proteins would have lost much
of their DNA transactivation and oligomerization do-
mains (including NLS), which we presume would result
in loss-of-function (as opposed to dominant-negative) gene
products, of which several of these frameshift mutant
alleles are annotated in human tumor TP53 curated
databases (Petitjean et al. 2007; Forbes et al. 2011). Never-
theless, we detected strong dominant-negative-like phe-
notypic increases in total p53 levels via immunoblots in all
DXR-resistant tumors (Fig. 3F), which, in the Em-myc
model, is often the result of allelic dominant-negative
inactivating mutations in Trp53 that interrupt the nega-
tive feedback loop brought on by p53-dependent trans-
activation of MDM2 (Eischen et al. 1999). Although we
did not confirm this via direct Trp53 transcript sequenc-
ing, we speculate that this might be the result of cose-
lection for dominant-negative-conferring mutations in
other non-Cas9 targeted exons. One of the top-ranked
mutant reads (labeled ‘‘A’’ and comprising ;6% of total
reads averaged across p53-modified Arf/Em-myc lym-
phomas) (Supplemental Fig. 7B,C) consists of a single A
insertion at the site of Cas9 cleavage shifting the reading
frame by +1 and prematurely terminating p53 translation
at an out-of-frame stop codon 27 codons downstream. In
fact, this mutation results in the deletion of ;12 kDa
from the C terminus and might correspond to the prom-
inent lower band detectable inWestern blots that migrates
;10 kDa lower than native p53 (Figs. 2E, 3F). The high
proportion of the single A insertion mutants reads could
have arisen from initial offset Cas9 cleavage events on
opposite DNA strands (Jinek et al. 2012), with the resulting
staggered ends undergoing repair and ligation (Supplemen-
tal Fig. 7B), thus biasing the resulting mutagenic outcome
and leading to the higher incidence of the single-base
insertion that we observed. Other common indels do
result in in-frame deletions that should drastically impair
transactivation function, but, in either case, further em-
pirical testing will be necessary to fully grasp their true
mutational role.
Off-target Cas9 cleavage events
For any large-scale CRISPR-based library, screening ef-
forts controlling for target specificity will be of para-
mount importance. Despite the degenerate nature of the
PAM and Cas9’s apparent tolerance for base mismatches
59 distal to its cleavage site and purported strict seed
region, early reports in both lower and higher model
organisms suggested minimal cutting at predicted off-
target genomic sites in situ (albeit often only circumstan-
tially) (Sapranauskas et al. 2011; Jinek et al. 2012; Cong
et al. 2013; Jiang et al. 2013a). While not an unbiased
genome-wide analysis, we devised a similar heuristic list
of probable p53 off-targets containing sequences that
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aligned genomically but conformed to 13 nt of an exactly
matching sequence 59 distal to the PAM and found very
little off-target cutting. We noted Cas9-driven modification
at one predicted site, a site bearing only two mismatches
(Fig. 4D, locus 7, positions 14 and 17 relative to PAM).
This was in stark contrast to another potential off-target
locus, the p53 pseudogene, for which we could not detect
any Cas9-driven mutations. Quite fortuitously, the p53
pseudogene also contains exactly two mismatches in its
trigger sequence, differing only in the locations of the
mismatches (Fig. 4C, positions 8 and 15 relative to PAM),
reinforcing the notion that Cas9 cleavage has a much less
stringent 59 end bias for mismatch tolerance. This also
underscores the fact that for purposes of sgRNA library
construction, much fewer gene-specific (or other geno-
mic-specific) sgRNAs will be needed to control for false
positive (or false negative) hits.
More recent work suggests that there is even greater
sequence degeneracy of DNA cleavage by Cas9, implying
that simple rules for off-target prediction will need to be
largely amended and expanded. Some reports suggest
substantial off-target mutagenesis (Cradick et al. 2013;
Fu et al. 2013), while others emphasized a more nuanced
portrait of Cas9 cleavage specificity (Hsu et al. 2013;
Pattanayak et al. 2013). One issue highlighted by these
reports is the importance in controlling both the amount
of Cas9/sgRNA delivered and the stoichiometry of
Cas9:sgRNA as determinants to limiting off-target cleav-
age. This is one key benefit designed into our constructs:
The combined amounts of each component (Cas9 and
sgRNA) would be fairly consistent upon cellular integra-
tion, which might explain the limited off-target muta-
genesis that we observed in vivo.Moving forward, there is
clearly a need for other unbiased in vivo techniques to
measure off-target editing events and for greater control
in maintaining Cas9 expression, perhaps through the use
of inducible systems. In sum, our results demonstrate
both the efficiency and simplicity of altering unique
genomic loci in a variety of settings using the retroviral-
based ‘‘all-in-one’’ Cas9–sgRNA plasmid, with seemingly
no apparent innate negative selection or off-target effects
following Cas9 expression in vivo.
Materials and methods
Vector design
The wild-type Cas9 gene sequence from S. pyogenes was mam-
malian codon-optimized using an online tool (http://www.encorbio.
com/protocols/Codon.htm) and synthesized by GenScript into
pUC57 (pUC57/Cas9) (Supplemental Fig. 1). The Cas9 D10A
mutation was engineered into pUC57/Cas9 by replacing the
NTD NcoI/KpnI fragment with a corresponding fragment har-
boring a GAC-to-GCC change. The Cas9 H840A mutation was
engineered into pUC57/Cas9 by replacing the BglII/HindIII
fragment by a corresponding gene fragment harboring the appro-
priate CAC-to-GCC alteration. The C-terminal Flag-tagged Cas9
variant was generated by removing the 3xFlag/NLS signals from
pUC57/Cas9 by replacing the NcoI/KpnI fragment with an
oligonucleotide and rebuilding the native Cas9 NTD. A synthetic
gene construct harboring the Cas9 CTD fused in-frame to 3xFlag
and SV40NLS signals was obtained fromGenScript, digestedwith
PmlI/ClaI, and inserted into the corresponding sites in the un-
tagged Cas9 variant. Full-length Cas9 variants were transferred
from pUC57 (NcoI [Klenow-repaired]–EcoRV fragment]) into
LeGo-iG (StuI–BsrGI [Klenow-repaired]) (http://www.lentigo-
vectors.de/vectors.htm) to generate pLC (Fig. 1A).
The pQ vector series was developed by gutting pQCXIX




AAAAGAACTGTTTAAACCAGCTG-39 (BglII and PvuII sites are
underlined). A BstXI/StuI fragment harboring the SV40 promoter
was isolated from MLS and inserted into the BstXI/EcoRV sites of
the above-described polylinker to generate pQ/SV40. The XbaI/
XhoI U6–sgRNA fragment was excised from pLC and inserted into
the same sites upstream of the SV40 promoter in pQ/SV40, to
generate pQ/U6/SV40. An EcoRI/ClaI (Klenow-repaired) fragment
harboring the EMCV IRES/GFP fragmentwas isolated fromMSCV-
IRES-GFP and cloned into the EcoRI/PvuII site of pQ/U6/SV40 to
generate pQ/U6/SV40-iG. Finally, the AflII (Klenow-repaired)/ClaI
Cas9 gene from pUC57/Cas9 was inserted into the BamHI
(Klenow-repaired)/ClaI sites of pQ/U6/SV40-iG to generate pQCiG.
sgRNA were ordered as gBlocks from IDT and cloned into
the HpaI–XhoI sites downstream from the human U6 promoter
in pLC.
Cell culture and lentiviral/retroviral infections
All retroviral packaging was performed using ecotropic Phoenix
cells according to established protocols (http://www.stanford.
edu/group/nolan/retroviral_systems/retsys.html). All murine
lymphomas used in this study were maintained in B-cell me-
dium (45% DMEM, 45% IMDM, 55 mM b-mercaptoethanol,
10% fetal bovine serum, 100 U/mL penicillin/streptomycin,
100 U/mL GLN) on g-irradiatedArf/MEF feeder layers. Feeder
layers were comprised of ;25% confluent g-irradiated Arf/
MEFs preincubated with B-cell medium for 3 d prior to addition
of lymphoma cells. Lymphomas were routinely split 1:3 every
2–3 d. MLP-p53.1224, an MSCV-based retrovirus that expresses
a potent p53 shRNA, has been described previously (Dickins
et al. 2005). U2OS cells weremaintained inMcCoy’s 5Amedium
supplementedwith 10% fetal bovine serum, 100U/mL penicillin/
streptomycin, and 100 U/mL Gln.
Lentiviral transductions were performed using second-genera-
tion vectors. Essentially, 10 mg of pLC, 7.5 mg of packaging plasmid
psPAX2, and 3 mg of envelope vector (pMDG2) were combined and
transfected by calcium phosphate into 293T/17 (American Type
Culture Collection) cells. The medium was changed the following
day, and, 48 h post-transfection, lentiviral supernatant was col-
lected every 8–12 h up until 72 h post-transfection. The lentiviral
supernatant (0.5 mL) was mixed with an equal volume of medium
and added to a well of a six-well dish containing U2OS target cells
that had been prepared at 60% confluency the previous day.
Following transduction, ;5–7 d were allowed to pass to allow
genome-editing events to occur, at which point assays were started.
TLR
The TLR assay was performed essentially as described by Certo
et al. (2011) and is described in the Supplemental Material.
Western blots
Total extracts were prepared by lysis in NuPAGE LDS sample
buffer. Subcellular fractionation was performed according to
a differential detergent fractionation procedure, as previously
described (Ramsby and Makowski 2011). Protein concentrations
CRISPR/Cas9 for in situ functional assays
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were determined using a DC protein assay (Bio-Rad), and extracts
were resolved by SDS-PAGE, transferred to PVDF membranes,
probed with the indicated antibodies, and visualized using
enhanced chemiluminescence (Perkin Elmer). The antibodies
used were directed against murine p53 (NCL-p53-505, Leica
Microsystems), human p53 (DO-1, Santa Cruz Biotechnology),
Flag tag (M2, Sigma), eEF2 (#2332, Cell Signaling), GFP (JL-8,
Clontech), GAPDH (14C10, Cell Signaling), VDAC (Ab-5,
Calbiochem), and hnRNPA1 (K350, Cell Signaling).
Flow cytometry
Tumors were harvested, and single-cell suspensions were pre-
pared by grinding tumors gently between the frosted portion of
two microscope slides followed by passing through a 40-mm cell
strainer (BD Falcon). These cells were treated with ACK buffer
(0.15 M NH4Cl, 0.1 mM EDTA, 0.01 M KHCO3 at pH 7.3) to
remove red blood cells, harvested by centrifugation, and washed
several times with ice-cold PBS. Cells were stained with pro-
pidium iodide (PI), and the forward, side scatter, PImeasurements,
and GFP content were assessed using a Guava EasyCyte HT. The
percent GFP+ cells was determined from the total viable cell
population using Guava ExpressPro software (Millipore).
Tumor transplantation studies
A total of 23 106 lymphoma cells was injected into the tail vein
of 6- to 8-wk-old female C57BL/6 mice. Upon development of
well-palpable tumors (auxiliary and inguinal lymph nodes;;2 wk
post-transplantation), mice were injected once intraperitoneally
with DXR. Tumor-free survival was defined as the time between
the disappearance and reappearance of a palpable lymphoma
following treatment. All animal studies were approved by the
McGill University Faculty of Medicine Animal Care Committee.
SURVEYOR assay
Genomic DNA was prepared from the indicated samples using
TNE buffer (10 mM Tris 8.0, 100 mM NaCl, 25 mM EDTA)
containing 0.15 mg/mL proteinase K, 0.15 mg/mL RNase A
(DNase-free), and 0.2% SDS. DNAwas extracted from nuclei by
incubating samples for 12 h at 45°C followed by phenol, phenol/
chloroform, and chloroform extraction. Samples were precipitated
in 2 vol of EtOH and one-tenth volume of 3 M NaOAc and
resuspended in ddH2O. The p53 target locus and predicted off-
target loci were amplified from genomic DNA using the primers
shown in Supplemental Table 1. PCR products were gel-purified
using QiaQuick Spin Columns (Qiagen). Mutations in the ampli-
cons were assessed using the SURVEYOR mutation detection kit
following the manufacturer’s guidelines (Transgenomic) and re-
solved on 10% nondenaturing polyacrylamide gels. Gels were
stained with ethidium bromide for 20 min followed by washing
with ddH2O for 20 min. Relative band intensities were quantified
using ImageJ (National Institutes of Health). One predicted off-
target locus (59-. . .aggtctaggtctAGCTCCTGCATGGAGGttcag. . .-39;
located 571,069 base pairs (bp) 59 to Agbl4 and 496,777 bp 39 from
Ntrk3 [Mus musculus strain C57BL/6J, chromosome 7, genomic
contig, GRCm38.p1 C57BL/6J MMCHR7_CTG5_2]) was not
analyzed in the present study as it consistently failed to yield
an amplicon after multiple PCR attempts.
Deep sequencing to assess mutation spectrum and targeting
specificity
Genomic regions flanking p53 and predicted CRISPR target sites
were amplified using barcoded primers with engineered adaptor
regions. Off-target loci (with the exception of #4 and #7) (Fig. 4D)
were amplified by PCR using Phusion HiFi polymerase (New
England Biolabs) with five cycles of annealing temperature at
56°C followed by 20 cycles with an annealing temperature of
68°C. Conditions used to PCR off-target locus #4 were the same;
however, Q5 HiFi polymerase (New England Biolabs) was used.
To amplify off-target locus #7, a touchdown PCR protocol with
Q5 HiFi polymerase (New England Biolabs) was used. The
annealing temperature was stepwise-reduced from 68°C to
56°C with 1°C decrease per cycle over 13 cycles followed by 15
cycles with an annealing temperature at 56°C. PCR products
were gel-purified using QiaQuick Spin Columns (Qiagen). DNA
samples were quantified using picogreen and pooled in equimo-
lar ratios. Sequencing libraries were then sequenced on an Ion
Torrent personal genome machine as recommended by the man-
ufacturer (Life Technologies).
Sequence reads were initially filtered requiring a perfect
sequencematch to barcodes and to PCR primers used to generate
the amplicons. Reads were further filtered by excluding reads
containing $4 bases with Phred quality scores <25 using
NextGENe software (Softgenetics). For all CRISPR target sites,
a wild-type sequence at the target site identified a nonedited
read. The inclusion of amplicons from cells that had been
targeted using the Rosa26 trigger acted as a negative control to
gauge the frequency of indels arising from non-CRIPSR/Cas9
events. For amplicons to the p53 pseudogene, a distinguish-
ing nucleotide difference (G in wild-type Trp53 vs. A in the
53 pseudogene) 5 bp downstream from the PAM site was used to
identify and bin the reads (Fig. 4C).
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